Vaudan Stéphanie, Ratano Damian, Beuret Philippe, Hauptmann John, Contal Olivier, Garin Nicolas
Department of Physiotherapy
Department of Intensive Care, University Hospital of Lausanne, Lausanne, Switzerland.
Respir Care. 2015 Oct;60(10):1404-8. doi: 10.4187/respcare.03844. Epub 2015 Jul 7.
Compared with usual care, noninvasive ventilation (NIV) lowers the risk of intubation and death for subjects with respiratory failure secondary to COPD exacerbations, but whether administration of NIV by a specialized, dedicated team improves its efficiency remains uncertain. Our aim was to test whether a dedicated team of respiratory therapists applying all acute NIV treatments would reduce the risk of intubation or death for subjects with COPD admitted for respiratory failure.
We carried out a retrospective study comparing subjects with COPD admitted to the ICU before (2001-2003) and after (2010-2012) the creation of a dedicated NIV team in a regional acute care hospital. The primary outcome was the risk of intubation or death. The secondary outcomes were the individual components of the primary outcome and ICU/hospital stay.
A total of 126 subjects were included: 53 in the first cohort and 73 in the second. There was no significant difference in the demographic characteristics and severity of respiratory failure. Fifteen subjects (28.3%) died or had to undergo tracheal intubation in the first cohort, and only 10 subjects (13.7%) in the second cohort (odds ratio 0.40, 95% CI 0.16-0.99, P = .04). In-hospital mortality (15.1% vs 4.1%, P = .03) and median stay (ICU: 3.1 vs 1.9 d, P = .04; hospital: 11.5 vs 9.6 d, P = .04) were significantly lower in the second cohort, and a trend for a lower intubation risk was observed (20.8% vs 11% P = .13).
The delivery of NIV by a dedicated team was associated with a lower risk of death or intubation in subjects with respiratory failure secondary to COPD exacerbations. Therefore, the implementation of a team administering all NIV treatments on a 24-h basis should be considered in institutions admitting subjects with COPD exacerbations.
与常规治疗相比,无创通气(NIV)可降低慢性阻塞性肺疾病(COPD)急性加重继发呼吸衰竭患者的插管和死亡风险,但由专业的专职团队进行NIV治疗是否能提高其效率仍不确定。我们的目的是测试由呼吸治疗师专职团队进行所有急性NIV治疗是否会降低因呼吸衰竭入院的COPD患者的插管或死亡风险。
我们进行了一项回顾性研究,比较了在一家地区急性护理医院成立专职NIV团队之前(2001 - 2003年)和之后(2010 - 2012年)入住重症监护病房(ICU)的COPD患者。主要结局是插管或死亡风险。次要结局是主要结局的各个组成部分以及ICU/住院时间。
共纳入126例患者:第一组53例,第二组73例。两组患者的人口统计学特征和呼吸衰竭严重程度无显著差异。第一组有15例患者(28.3%)死亡或必须接受气管插管,而第二组只有10例患者(13.7%)(比值比0.40,95%可信区间0.16 - 0.99,P = 0.04)。第二组的住院死亡率(15.1%对4.1%,P = 0.03)和中位住院时间(ICU:3.1天对1.9天,P = 0.04;医院:11.5天对9.6天,P = 0.04)显著更低,并且观察到插管风险有降低趋势(20.8%对11%,P = 0.13)。
由专职团队进行NIV治疗与COPD急性加重继发呼吸衰竭患者的死亡或插管风险降低相关。因此,在收治COPD急性加重患者的机构中,应考虑实施一个24小时进行所有NIV治疗的团队。